205 related articles for article (PubMed ID: 27875783)
1. PRAME overexpression predicted good outcome in pediatric B-cell acute lymphoblastic leukemia patients receiving chemotherapy.
Zhang YH; Lu AD; Yang L; Li LD; Chen WM; Long LY; Zhang LP; Qin YZ
Leuk Res; 2017 Jan; 52():43-49. PubMed ID: 27875783
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP).
Consolini R; Legitimo A; Rondelli R; Guguelmi C; Barisone E; Lippi A; Cantù-Rajnoldi A; Aricò M; Conter V; Cocito MG; Putti MC; Pession A; Masera G; Biondi A; Basso G
Haematologica; 1998 Nov; 83(11):967-73. PubMed ID: 9864914
[TBL] [Abstract][Full Text] [Related]
3. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Cario G; Rhein P; Mitlöhner R; Zimmermann M; Bandapalli OR; Romey R; Moericke A; Ludwig WD; Ratei R; Muckenthaler MU; Kulozik AE; Schrappe M; Stanulla M; Karawajew L
Haematologica; 2014 Jan; 99(1):103-10. PubMed ID: 23911702
[TBL] [Abstract][Full Text] [Related]
4. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
5. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance.
Dworzak MN; Fritsch G; Panzer-Grümayer ER; Mann G; Gadner H
Leuk Lymphoma; 2000 Jul; 38(3-4):295-308. PubMed ID: 10830736
[TBL] [Abstract][Full Text] [Related]
6. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
Lepretre S; Touzart A; Vermeulin T; Picquenot JM; Tanguy-Schmidt A; Salles G; Lamy T; Béné MC; Raffoux E; Huguet F; Chevallier P; Bologna S; Bouabdallah R; Benichou J; Brière J; Moreau A; Tallon-Simon V; Seris S; Graux C; Asnafi V; Ifrah N; Macintyre E; Dombret H
J Clin Oncol; 2016 Feb; 34(6):572-80. PubMed ID: 26644537
[TBL] [Abstract][Full Text] [Related]
7. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
Santamaría C; Chillón MC; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Ramos F; Bernal T; Queizán JA; Peñarrubia MJ; Giraldo P; San Miguel JF; Gonzalez M
Haematologica; 2008 Dec; 93(12):1797-805. PubMed ID: 18815192
[TBL] [Abstract][Full Text] [Related]
8. Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia.
Spanaki A; Perdikogianni C; Linardakis E; Kalmanti M
Leuk Res; 2007 May; 31(5):639-42. PubMed ID: 16860864
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease-based treatment is adequate for relapse-prone childhood acute lymphoblastic leukemia with an intrachromosomal amplification of chromosome 21: the experience of the ALL-BFM 2000 trial.
Attarbaschi A; Panzer-Grümayer R; Mann G; Möricke A; König M; Mecklenbräuker A; Teigler-Schlegel A; Bradtke J; Harbott J; Göhring G; Stanulla M; Schrappe M; Zimmermann M; Haas OA;
Klin Padiatr; 2014 Nov; 226(6-7):338-43. PubMed ID: 25431866
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of childhood lymphoblastic lymphoma in Shanghai China 2001-2010.
Gao YJ; Pan C; Tang JY; Lu FJ; Chen J; Xue HL; Zhai XW; Li J; Ye QD; Zhou M; Wang HS; Miao H; Qian XW; Xu Z; Meng JH
Pediatr Blood Cancer; 2014 Apr; 61(4):659-63. PubMed ID: 24243691
[TBL] [Abstract][Full Text] [Related]
11. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
Ratei R; Schabath R; Karawajew L; Zimmermann M; Möricke A; Schrappe M; Ludwig WD
Klin Padiatr; 2013 May; 225 Suppl 1():S34-9. PubMed ID: 23700065
[TBL] [Abstract][Full Text] [Related]
12. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia.
Troeger A; Siepermann M; Escherich G; Meisel R; Willers R; Gudowius S; Moritz T; Laws HJ; Hanenberg H; Goebel U; Janka-Schaub GE; Mahotka C; Dilloo D
Haematologica; 2007 Aug; 92(8):1043-50. PubMed ID: 17640858
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of Wilms' tumor gene 1 (WT1) expression at diagnosis in adults with Ph-negative B cell precursor acute lymphoblastic leukemia.
Qin YZ; Jiang Q; Xu LP; Jiang H; Wang Y; Zhao XS; Li ZR; Lai YY; Liu YR; Zhang XH; Liu KY; Huang XJ
Ann Hematol; 2019 Nov; 98(11):2551-2559. PubMed ID: 31493003
[TBL] [Abstract][Full Text] [Related]
14. PRAME gene expression in childhood acute lymphoblastic leukemia.
Steinbach D; Viehmann S; Zintl F; Gruhn B
Cancer Genet Cytogenet; 2002 Oct; 138(1):89-91. PubMed ID: 12419593
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
16. PRAME gene expression in childhood acute lymphoblastic leukemia: impact on prognosis.
Abdelmalak CA; Yahya RS; Elghannam DM; El-Khadragy AE; Abd El Messih HM
Clin Lab; 2014; 60(1):55-61. PubMed ID: 24600975
[TBL] [Abstract][Full Text] [Related]
17. Precursor B- or T-lymphoblastic lymphoma presenting with cutaneous involvement: a series of 13 cases including 7 cases of cutaneous T-lymphoblastic lymphoma.
Lee WJ; Moon HR; Won CH; Chang SE; Choi JH; Moon KC; Lee MW
J Am Acad Dermatol; 2014 Feb; 70(2):318-25. PubMed ID: 24314877
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of clinical features and prognostic significance of childhood T-lineage acute lymphoblastic leukemia].
Zhang YL; Zhao WL; Nie SS; Guo DD; Ji ZH; Chai YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1496-500. PubMed ID: 22169311
[TBL] [Abstract][Full Text] [Related]
19. CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol.
Ghazavi F; Clappier E; Lammens T; Suciu S; Caye A; Zegrari S; Bakkus M; Grardel N; Benoit Y; Bertrand Y; Minckes O; Costa V; Ferster A; Mazingue F; Plat G; Plouvier E; Poirée M; Uyttebroeck A; van der Werff-Ten Bosch J; Yakouben K; Helsmoortel H; Meul M; Van Roy N; Philippé J; Speleman F; Cavé H; Van Vlierberghe P; De Moerloose B
Haematologica; 2015 Oct; 100(10):1311-9. PubMed ID: 26137961
[TBL] [Abstract][Full Text] [Related]
20. Cysteine and glycine-rich protein 2 (CSRP2) transcript levels correlate with leukemia relapse and leukemia-free survival in adults with B-cell acute lymphoblastic leukemia and normal cytogenetics.
Wang SJ; Wang PZ; Gale RP; Qin YZ; Liu YR; Lai YY; Jiang H; Jiang Q; Zhang XH; Jiang B; Xu LP; Huang XJ; Liu KY; Ruan GR
Oncotarget; 2017 May; 8(22):35984-36000. PubMed ID: 28415593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
